Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …

Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed
numerous and exciting developments in chronic thromboembolic pulmonary hypertension (…

Background— Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel
of venous thromboembolism with fatal natural history; however, many cases can be cured by …

Objectives : Our goal was to investigate the effect of treatment with the oral dual endothelin
receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with …

Background— Chronic thromboembolic pulmonary hypertension, a rare complication of acute
pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary …

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …

BACKGROUND Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine
monophosphate signaling results from endothelial dysfunction and may underlie impaired cardiac …

Background Macitentan is beneficial for long-term treatment of pulmonary arterial
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …